Statins and ARBs on Rheumatoid Activity
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03770702 |
Recruitment Status :
Recruiting
First Posted : December 10, 2018
Last Update Posted : December 10, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rheumatoid Arthritis | Drug: Angiotensin receptor blockers Drug: Statins | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 45 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Investigational and Comparative Study Between the Anti-inflammatory Effectof Both Angiotensin Reeptor Blockers and Statins on Rheumatoid Arthritis Disease Activity on Egyptian Patients |
Actual Study Start Date : | October 1, 2018 |
Estimated Primary Completion Date : | December 1, 2025 |
Estimated Study Completion Date : | December 1, 2026 |

Arm | Intervention/treatment |
---|---|
No Intervention: Control group
No intervention
|
|
Active Comparator: Angiotensin receptor blockers
ARB ( Angiotensin receptor blockers) + Traditional therpy.
|
Drug: Angiotensin receptor blockers
Candesartan
Other Name: Cansartan |
Active Comparator: Statins
Statin + Traditional therapy.
|
Drug: Statins
Atorvastatin
Other Name: Ator |
- Change in disease activity score [ Time Frame: 6 months ]DAS28-ESR

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Rheumatoid arthritis.
Exclusion Criteria:
- Pregnant or lactating
- Hepatic or renal impairment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03770702
Contact: Sherief Abd-Elsalam, Ph D | 00201147773440 | sheriefabdelsalam@yahoo.com |
Egypt | |
Sherief Abd-Elsalam | Recruiting |
Tanta, Egypt, 35111 | |
Contact: Ahmed El-Abd, Msc |
Principal Investigator: | Sahar K Hegazy, Prof | Head of Clinical Pharmacy Department | |
Study Director: | Tarek M Mostafa, Prof | Prof of Clinical Pharmacy | |
Study Chair: | Emad M Elshebini, MD | Rheumatology Dept. - Menoufia University | |
Study Chair: | Ahmed HM El-Abd, Msc | Clinical pharmacy Department-Tanta University |
Responsible Party: | Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University |
ClinicalTrials.gov Identifier: | NCT03770702 |
Other Study ID Numbers: |
Rheumatoid |
First Posted: | December 10, 2018 Key Record Dates |
Last Update Posted: | December 10, 2018 |
Last Verified: | December 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Arthritis Arthritis, Rheumatoid Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action |